Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β- d -Glucan Synthase: Implication for the Existing Susceptibility Breakpoint
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Thirteen Candida glabrata strains harboring a range of mutations in hot spot regions of FKS1 and FKS2 were studied. The mutations were linked to an echinocandin reduced susceptibility phenotype. Sequence alignments showed that 11 out of the 13 mutants harbored a mutation in FKS1 or FKS2 not previously implicated in echinocandin reduced susceptibility in C. glabrata . A detailed kinetic characterization demonstrated that amino acid substitutions in Fks1p and Fks2p reduced drug sensitivity in mutant 1,3-β- d -glucan synthase by 2 to 3 log orders relative to that in wild-type enzyme. These mutations were also found to reduce the catalytic efficiency of the enzyme ( V max ) and to influence the relative expression of FKS genes. In view of the association of FKS mutations and reduced susceptibility of 1,3-β- d -glucan synthase, an evaluation of the new CLSI echinocandin susceptibility breakpoint was conducted. Only 3 of 13 resistant fks mutants (23%) were considered anidulafungin or micafungin nonsusceptible (MIC > 2 μg/ml) by this criterion. In contrast, most fks mutants (92%) exceeded a MIC of >2 μg/ml with caspofungin. However, when MIC determinations were performed in the presence of 50% serum, all C. glabrata fks mutants showed MICs of ≥2 μg/ml for the three echinocandin drugs. As has been observed with Candida albicans , the kinetic inhibition parameter 50% inhibitory concentration may be a better predictor of FKS -mediated resistance. Finally, the close association between FKS1/FKS2 hot spot mutations provides a basis for understanding echinocandin resistance in C. glabrata .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“C. glabrata may upregulate FKS2 expression to compensate for its decreased catalytic capacity [36]”
From Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata (2012) · cites this paper as [36]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As with azoles, resistance to echinocandin therapy frequently involves mutations in genes encoding the drug target, FKS1 (Candida, Cryptococcus, and Aspergillus spp.) and FKS2 (C. glabrata only)33,34.”
From Molecular mechanisms governing antifungal drug resistance (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“intrinsic genetic, structural, and binding variations in Fks enzymes across Candida species create distinct baseline susceptibilities and predispose certain species to develop heteroresistance under selective pressure from specific echinocandins [51].”
From Calcineurin‐Dependent Stress Adaptation Enables Caspofungin Heteroresistance Leading to Stable Resistance in Candida Glabrata (2026) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, FKS1 point mutations are commonly detected in ECN-resistant (ECN-R) Candida spp. (24, 25).”
From Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris (2022) · cites this paper as [24]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Point mutations in one of two specific hot-spot regions of FKS genes increase the half maximal inhibition concentration (IC50) of an echinocandin in vitro by up to 3 orders of magnitude67.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [67]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics
White, T. J., Bruns, T., Lee, S., & Taylor, J. (1990) · PCR Protocols · doi:10.1016/b978-0-12-372180-8.50042-1 · Cited by 36,648
Self-citationA new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610 · cited 1×
“relative expression levels were evaluated using the Pfaffl method (23).”
MethodPCR protocols — A guide to methods and applications
(1990) · Trends in Genetics · doi:10.1016/0168-9525(90)90186-a · Cited by 11,781
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“glabrata infections are a concern due to their high mortality rates (38) and the tendency of this microorganism to rapidly develop resistance to azole antifungal agents (6, 11, 15, 25, 31, 34).”
BackgroundDenning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 1×
“The introduction of the antifungal drug caspofungin (CSF) in 2001 was a significant advance in the treatment of these infections since these lipopeptides’ mode of action is independent of existing antifungal drugs (7, 16, 36).”
BackgroundReference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard
Rex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 1,052
Fidel, P. L., Vazquez, J. A., & Sobel, J. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.80 · Cited by 953 · cited 1×
“glabrata infections are a concern due to their high mortality rates (38) and the tendency of this microorganism to rapidly develop resistance to azole antifungal agents (6, 11, 15, 25, 31, 34).”
BackgroundTrick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Resistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512 · cited 3×
“These IC50s were comparable with previous data obtained for other echinocandin-resistant Candida species strains with FKS mutations (13, 14, 21, 22).”
BackgroundResultSelf-citationPark, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Self-citation
Cited by
Items 101–200 of 335
EUCAST technical note on anidulafungin
Arendrup, M. C., Rodriguez-Tudela, J.-L., Lass-Flörl, C., Cuenca-Estrella, M., Donnelly, J. P., & Hope, W. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03647.x · Cited by 60
“A number of in vitro studies on susceptibility of the fungus, of the target enzyme itself or in animal models have demonstrated cross-resistance between the three currently available echinocandins (anidulafungin, caspofungin and micafungin) for isolates with hot spot mutations in the target gene [3,10–15].”
BackgroundBédard, C., Pageau, A., Fijarczyk, A., Mendoza-Salido, D., Alcañiz, A. J., Després, P. C., Durand, R., Plante, S., Alexander, E. M. M., Rouleau, F. D., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02084-7 · Cited by 67
Martins, I. M., Cortés, J. C. G., Muñoz-García, J., Moreno, M. B., Ramos, M., Clemente‐Ramos, J. Á., Durán, Á., & Ribas, J. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.174300 · Cited by 72
Ramage, G., Jose, A., Coco, B. J., Rajendran, R., Rautemaa‐Richardson, R., Murray, C. A., Lappin, D. F., & Bagg, J. (2011) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2010.10.043 · Cited by 73
“There are, however, caveats to this approach, because recent data reported echinocandin resistance through the FKS1 and FKS2 gene loci.(20,22) Although this is still relatively rare, caution should be exercised regarding its overuse, because resistance has been described in several Candida spp.”
ResultAntifungal drug resistance in Candida: a special emphasis on amphotericin B
Ahmady, L., Gothwal, M., Mukkoli, M. M., & Bari, V. K. (2024) · Apmis · doi:10.1111/apm.13389 · Cited by 65
“Inaddition, genetic alterations in FKS1 and its paralog FKS2 are strongly related to the emergence of echinocandin resistance in Candida species [127].”
BackgroundGarnaud, C., Botterel, F., Sertour, N., Bougnoux, M.-E., Dannaoui, E., Larrat, S., Hennequin, C., Guinea, J., Cornet, M., & Maubon, D. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv139 · Cited by 55
Potential Strategies to Control the Risk of Antifungal Resistance in Humans: A Comprehensive Review
Rabaan, A. A., Sulaiman, T., Al-Ahmed, S. H., Buhaliqah, Z. A., Buhaliqah, A. A., AlYuosof, B., Alfaresi, M. S., Fares, M. A. A., Alwarthan, S. M., Alkathlan, M. S., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12030608 · Cited by 67
Healey, K. R., Nagasaki, Y., Zimmerman, M., Kordalewska, M., Park, S., Zhao, Y., & Perlin, D. S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01412-17 · Cited by 57
“Cell disruption, membrane protein extraction, and partial 1,3- -D-glucan synthase purification by-product entrapment were performed as previously described (42).”
MethodSelf-citationSalazar, S. B., Simões, R., Pedro, N. A., Pinheiro, M. J. F., Carvalho, M. F. N. N., & Mira, N. P. (2020) · Journal of Fungi · doi:10.3390/jof6010023 · Cited by 63
Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin
Fekkar, A., Meyer, I., Brossas, J. Y., Dannaoui, E., Palous, M., Uzunov, M., Nguyen, S., Leblond, V., Mazier, D., & Datry, A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02037-12 · Cited by 56
Papp, C., Kocsis, K., Tóth, R., Bodai, L., Willis, J. R., Ksiezopolska, E., Lozoya-Pérez, N. E., Vágvölgyi, C., Mora Montes, H., Gabaldón, T., et al. (2018) · mSphere · doi:10.1128/msphere.00547-18 · Cited by 50
“parapsilosis strains, the corresponding substitution may be responsible for a strong cross-resistance to echinocandins (21, 22).”
BackgroundPham, C. D., Bolden, C. B., Kuykendall, R. J., & Lockhart, S. R. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.03378-13 · Cited by 51
“This mutation was not included in our original assay but does confer echinocandin resistance (10, 13).”
BackgroundMethodPerlin, D. S., & Wiederhold, N. P. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix121 · Cited by 49
Self-citationLee, K. K., Kubo, K., Abdelaziz, J. A., Cunningham, I., de Silva Dantas, A., Chen, X., Okada, H., Ohya, Y., & Gow, N. A. R. (2018) · The Cell Surface · doi:10.1016/j.tcsw.2018.09.001 · Cited by 52
“The accumulation of point mutations in one of three hot spot regions of Fks1 has been shown to confer echinocandin resistance (Garcia-Effron et al., 2009a; Garcia-Effron et al., 2010; Perlin, 2011; Arendrup et al., 2014; Perlin, 2015b; Kolaczkowska et al., 2016).”
Shields, R. K., Kline, E. G., Healey, K. R., Kordalewska, M., Perlin, D. S., Nguyen, M. H., & Clancy, C. J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01692-18 · Cited by 51
“Mutations at these loci are associated with the highest echinocandin IC50s (14).”
BackgroundMethodSelf-citationAl-Baqsami, Z. F., Ahmad, S., & Khan, Z. (2020) · Scientific Reports · doi:10.1038/s41598-020-63240-z · Cited by 49
Pfaller, M. A., Diekema, D. J., Jones, R. N., & Castanheira, M. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.00782-14 · Cited by 51
“glabrata (655) Anidulafungin 1 72 (1) 282 (6) 228 (4) 30 (6) 4 (3) 21 (20) 9 (8) 8 (7) Caspofungin 37 334 (1) 210 (6) 20 (3) 10 (6) 13 (10) 7 (6) 8 (8) 2 (2) 14 (13)”
Klotz, U., Schmidt, D., Willinger, B., Steinmann, E., Buer, J., Rath, P., & Steinmann, J. (2016) · Mycoses · doi:10.1111/myc.12472 · Cited by 49
Biswas, C., Marcelino, V. R., Van Hal, S., Halliday, C., Martinez, E., Wang, Q., Kidd, S., Kennedy, K., Marriott, D., Morrissey, C. O., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02946 · Cited by 49
“The FKS1 mutation Ser629Pro (in one isolate) and the mutation FKS2 Ser663Pro (three isolates) identified are among the most common in C. glabrata strains with high-level resistance phenotypes (Garcia-Effron et al., 2009; Arendrup and Perlin, 2014).”
BackgroundDudiuk, C., Gamarra, S., Leonardeli, F., Jimenez-Ortigosa, C., Vitale, R. G., Afeltra, J., Perlin, D. S., & Garcia-Effron, G. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01038-14 · Cited by 50
“However, this molecular mechanism of echinocandin resistance has been described in only few strains worldwide and it is the least common substitution at this residue (8, 16, 19).”
BackgroundSelf-citationNiimi, K., Monk, B. C., Hirai, A., Hatakenaka, K., Umeyama, T., Lamping, E., Maki, K., Tanabe, K., Kamimura, T., Ikeda, F., et al. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq073 · Cited by 48
Reconstruction and analysis of the genome-scale metabolic network of Candida glabrata
Xu, N., Liu, L., Zou, W., Liu, J., Hua, Q., & Chen, J. (2012) · Molecular BioSystems · doi:10.1039/c2mb25311a · Cited by 54
An Introduction to the Medically Important Candida Species
Moran, G., Coleman, D., & Sullivan, D. (2014) · Candida and Candidiasis · doi:10.1128/9781555817176.ch2 · Cited by 40
Fuller, J., Dingle, T. C., Bull, A., Shokoples, S., Laverdière, M., Baxter, M. R., Adam, H. J., Karlowsky, J. A., Zhanel, G. G., Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD, et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz287 · Cited by 52
Can We Improve Antifungal Susceptibility Testing?
Durand, C., Maubon, D., Cornet, M., Wang, Y., Aldebert, D., & Garnaud, C. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.720609 · Cited by 52
“Resistance of Candida spp. to echinocandins is associated with amino-acid substitutions in the FKS genes which encode their target: the 1,3-b-D-glucan synthase (Katiyar et al., 2006; Perlin, 2007; Garcia-Effron et al., 2009).”
BackgroundBlanchard, E., Lortholary, O., Boukris-Sitbon, K., Desnos-Ollivier, M., Dromer, F., Guillemot, D., & the French Mycosis Study Group (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00690-11 · Cited by 48
“orthopsilosis) and Candida guilliermondii are intrinsically less susceptible than other Candida species to echinocandin due to naturally occurring point mutations in the FKS gene (6, 10, 19, 26).”
BackgroundEchinocandin Resistance in Candida Species Isolates from Liver Transplant Recipients
Prigent, G., Aït-Ammar, N., Levesque, E., Fekkar, A., Costa, J.-M., El Anbassi, S., Foulet, F., Duvoux, C., Merle, J.-C., Dannaoui, E., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01229-16 · Cited by 44
Rivero-Menéndez, O., Navarro-Rodríguez, P., Bernal‐Martínez, L., Martin-Cano, G., Lopez-Perez, L., Sánchez‐Romero, I., Pérez‐Ayala, A., Capilla, J., Zaragoza, Ó., & Alastruey‐Izquierdo, A. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01585 · Cited by 47
Emerging Issues in Antifungal Resistance
Perfect, J. R., & Ghannoum, M. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.05.003 · Cited by 47
Bader, J. C., Lakota, E. A., Flanagan, S., Ong, V., Sandison, T., Rubino, C. M., Bhavnani, S. M., & Ambrose, P. G. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02614-17 · Cited by 45
Astvad, K. M., Perlin, D. S., Johansen, H. K., Jensen, R. H., & Arendrup, M. C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01382-12 · Cited by 43
“However, this has been challenging using classical susceptibility testing techniques due to overlap or poor separation of wt and fks hot spot mutant isolates (10, 11, 15, 16).”
BackgroundMethodSelf-citationWiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Pizzini, J., Catano, G., & Patterson, T. F. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx422 · Cited by 43
Echinocandin Resistance in Candida Species: a Review of Recent Developments
Wiederhold, N. P. (2016) · Current Infectious Disease Reports · doi:10.1007/s11908-016-0549-2 · Cited by 49
Emergence of resistant Candida glabrata in Germany
Aldejohann, A. M., Herz, M., Martin, R., Walther, G., & Kurzai, O. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab122 · Cited by 41
Lepak, A., Castanheira, M., Diekema, D., Pfaller, M., & Andes, D. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-12 · Cited by 41
Our 2014 approach to breakthrough invasive fungal infections
Maschmeyer, G., & Patterson, T. F. (2014) · Mycoses · doi:10.1111/myc.12213 · Cited by 43
The Antifungal Occidiofungin Triggers an Apoptotic Mechanism of Cell Death in Yeast
Emrick, D., Ravichandran, A., Gosai, J., Lu, S., Gordon, D. M., & Smith, L. (2013) · Journal of Natural Products · doi:10.1021/np300678e · Cited by 47
Hou, X., Xiao, M., Wang, H., Yu, S.-Y., Zhang, G., Zhao, Y., & Xu, Y.-C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00153-18 · Cited by 40
Occidiofungin's Chemical Stability and In Vitro Potency against Candida Species
Ellis, D., Gosai, J., Emrick, C., Heintz, R., Romans, L., Gordon, D. M., Lu, S., Austin, F. W., & Smith, L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05231-11 · Cited by 47
“The antifungal activity of echinocandins is attributed to selective inhibition of 1,3- -glucan synthesis by their function as noncompetitive inhibitors of 1,3- -glucan synthase (5, 9, 14, 17, 27).”
BackgroundKim, H. Y., Baldelli, S., Märtson, A., STOCKER, S. L., Alffenaar, J. C., Cattaneo, D., & Marriott, D. J. E. (2021) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000931 · Cited by 42
McTaggart, L. R., Cabrera, A. L., Cronin, K. I., & Kus, J. V. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00402-20 · Cited by 39
“These mutations render 1,3-beta-glucan synthase impervious to echinocandin activity (7, 18, 19).”
BackgroundMesser, S. A., Jones, R. N., Moet, G. J., Kirby, J. T., & Castanheira, M. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00328-10 · Cited by 35
“glabrata strains harbored mutations encoding the S645P fks1 HS1 alteration, corroborating prior observations (8, 10), and that the three remaining isolates exhibited fks2 HS1 alterations (S645F, 1 strain; S645P, 2 strains).”
BackgroundResultSpreghini, E., Orlando, F., Sanguinetti, M., Posteraro, B., Giannini, D., Manso, E., & Barchiesi, F. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05872-11 · Cited by 37
“(13) performed a genetic analysis of FKS1 and FKS2 genes from 13 echinocandin-resistant C.”
BackgroundAntifungal Activity, Toxicity, and Membranolytic Action of a Mastoparan Analog Peptide
Singulani, J. D. L., Galeane, M. C., Ramos, M. D., Gomes, P. C., dos Santos, C. T., de Souza, B. M., Palma, M. S., Fusco‐Almeida, A. M., & Mendes‐Giannini, M. J. S. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00419 · Cited by 40
“These mutations result in amino acid substitutions and consequently, in different phenotypes of glucan synthase that alter the drug-target interactions (Garcia-Effron et al., 2009; Perlin, 2015).”
BackgroundCosta-de-Oliveira, S., Marcos Miranda, I., Silva, R. M., Pinto e Silva, A., Rocha, R., Amorim, A., Gonçalves Rodrigues, A., & Pina-Vaz, C. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00589-10 · Cited by 37
Biswas, C., Chen, S. C.-A., Halliday, C., Kennedy, K., Playford, E. G., Marriott, D. J., Slavin, M. A., Sorrell, T. C., & Sintchenko, V. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.03.014 · Cited by 36
Garcia-Rubio, R., Hernandez, R. Y., Clear, A., Healey, K. R., Shor, E., & Perlin, D. S. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.702779 · Cited by 35
“Thus, it is possible that some or all mutants isolated in our study that show a CRSMIS-like phenotype also have altered membrane sphingolipid composition, resulting in these particular changes in GS sensitivity to echinocandin class drugs.”
ResultSelf-citationKhalifa, H. O., Majima, H., Watanabe, A., & Kamei, K. (2021) · Journal of Fungi · doi:10.3390/jof7020108 · Cited by 37
“used as first-line therapy for invasive candidiasis and act by inhibiting fungal cell wall synthesis through non-competitive inhibition of 1, 3-β-D-glucan synthase [3].”
BackgroundMethodInfluentialSurface coatings with covalently attached caspofungin are effective in eliminating fungal pathogens
Coad, B. R., Lamont-Friedrich, S. J., Gwynne, L., Jasieniak, M., Griesser, S. S., Traven, A., Peleg, A. Y., & Griesser, H. J. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb00961h · Cited by 37
Bouklas, T., Alonso-Crisóstomo, L., Székely, T., Diago-Navarro, E., Orner, E. P., Smith, K., Munshi, M. A., Del Poeta, M., Balázsi, G., & Fries, B. C. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006355 · Cited by 34
Interactions of Yeasts, Moulds, and Antifungal Agents: How to Detect Resistance
Hall, G. S. (2011) · Humana Press eBooks · doi:10.1007/978-1-59745-134-5 · Cited by 43
Jenull, S., Shivarathri, R., Tsymala, I., Penninger, P., Trinh, P.-C., Nogueira, F., Chauhan, M., Singh, A., Petryshyn, A., Stoiber, A., et al. (2022) · mBio · doi:10.1128/mbio.00799-22 · Cited by 32
Barber, A. E., Weber, M., Kaerger, K., Linde, J., Gölz, H., Duerschmied, D., Markert, A., Guthke, R., Walther, G., & Kurzai, O. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01628-18 · Cited by 32
“Moreover, despite the fact that the S633P mutation in FKS2 comes at a fitness cost to the organism in the absence of echinocandins (16, 20), we did not observe any significant growth differences between CBS 138, NRZ-2016-057, and NRZ-2016-058 in RPMI or YPD medium (data not shown), suggesting that one or more of the u…”
BackgroundBeyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways
Hetta, H. F., Melhem, T., Aljohani, H. M., Salama, A., Ahmed, R., Elfadil, H., Alanazi, F. E., Ramadan, Y. N., Battah, B., Rottura, M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18030364 · Cited by 35
García‐Effrón, G., Park, S., & Perlin, D. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01350-10 · Cited by 35
“However, it has been demonstrated that the CLSI breakpoints are not able to distinguish all the echinocandin-resistant fks mutants from wild-type (WT) isolates (2, 15, 16), which led us to propose new interpretative MIC breakpoints for the echinocandins against Candida species (for echinocandins against C.”
BackgroundMethodResultInfluentialSelf-citationAmanloo, S., Shams-Ghahfarokhi, M., Ghahri, M., & Razzaghi-Abyaneh, M. (2018) · Medical Mycology · doi:10.1093/mmy/myx030 · Cited by 30
Jaber, Q. Z., Bibi, M., Księżopolska, E., Gabaldón, T., Berman, J. G., & Fridman, M. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00813 · Cited by 35
Viana, R., Dias, Ó., Lagoa, D., Galocha, M., Rocha, I., & Teixeira, M. C. (2020) · Journal of Fungi · doi:10.3390/jof6030171 · Cited by 37
“They are not considered essential as the enzyme beta-1,3-glucan synthase can be encoded by more than one FKS/GSC/GSL genes [77].”
BackgroundEUCAST and CLSI: Working Together Towards a Harmonized Method for Antifungal Susceptibility Testing
Espinel‐Ingroff, A., Cuenca‐Estrella, M., & Cantón, E. (2013) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0125-7 · Cited by 34
Salazar, S. B., Wang, C., Münsterkötter, M., Okamoto, M., Takahashi-Nakaguchi, A., Chibana, H., Lopes, M. M., Güldener, U., Butler, G., & Mira, N. P. (2018) · FEMS Yeast Research · doi:10.1093/femsyr/fox079 · Cited by 31
Bataineh, M. T. A., Sutton, D. A., Fothergill, A. W., & Wiederhold, N. P. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.014 · Cited by 30
“demonstrated differences in echinocandin potency in inhibiting the (1,3)-b-D-glucan synthase enzyme and changes in in vivo efficacy with echinocandin therapy in experimental models between isolates harboring different mutations.(136,137)”
BackgroundRole of FKS Gene in the Susceptibility of Pathogenic Fungi to Echinocandins
Hori, Y., & Shibuya, K. (2018) · Medical Mycology Journal · doi:10.3314/mmj.18.004 · Cited by 30
García‐Effrón, G. (2021) · Journal of Fungi · doi:10.3390/jof7030197 · Cited by 31
Goemaere, B., Lagrou, K., Spriet, I., Hendrickx, M., & Becker, P. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00591-18 · Cited by 32
“Although AFG, caspofungin (CAS), and MFG belong to the same class of antifungals, it is possible that they bind to different sites on the glucan synthase complex, reflected by unique resistance mutations (14).”
BackgroundShort-term evolution strategies for host adaptation and drug escape in human fungal pathogens
Beekman, C. N., & Ene, I. V. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008519 · Cited by 31
Healey, K. R., Katiyar, S. K., Castanheira, M., Pfaller, M. A., & Edlind, T. D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00044-11 · Cited by 30
“Resistance to date in clinical isolates has been strictly associated with mutations in the putative -1,3-glucan synthases Fks1 and Fks2 and is typically characterized by CSP, MCF, and ANF cross-resistance (1, 2, 6, 8, 13, 14, 18).”
BackgroundRodrigues, C. F., & Henriques, M. (2018) · Genes · doi:10.3390/genes9040205 · Cited by 32
“Generally, in the C. glabrata strains, a 24 h contact with both echinocandins upregulated FKS1 and FKS2 genes and, in the reference strain, the presence of Mcf upregulated FKS1.”
BackgroundInfluentialEchinocandin Failure Case Due to a Previously Unreported FKS1 Mutation in Candida krusei
Jensen, R. H., Justesen, U. S., Rewes, A., Perlin, D. S., & Arendrup, M. C. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02367-14 · Cited by 28
“Similar discrete MIC elevations were found in Candida glabrata with the equivalent substitution D632Y (9, 30), while the combination with a nonsense mutation (D632Y plus R1377STOP) was associated with high echinocandin resistance (31).”
BackgroundSelf-citationArendrup, M. C., Park, S., Brown, S., Pfaller, M., & Perlin, D. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01373-10 · Cited by 27
“This is in agreement with the previously reported differentiated changes in the drug susceptibility of the glucan synthase enzyme (9).”
ResultSelf-citationDurán-Valle, M. T., Gago, S., Gómez-López, A., Cuenca-Estrella, M., Jiménez Díez-Canseco, L., Gómez-Garcés, J. L., & Zaragoza, O. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06100-11 · Cited by 26
Two echinocandin-resistant Candida glabrata FKS mutants from South Africa
Naicker, S. D., Magobo, R. E., Zulu, T. G., Maphanga, T. G., Luthuli, N., Lowman, W., & Govender, N. P. (2016) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2016.03.004 · Cited by 24
“Previously, a nonsense mutation at FKS 2 hotspot 2 has been described where arginine was replaced with a stop codon at amino acid position 1377 [2].”
BackgroundEchinocandins as alternative treatment for HIV-infected patients with Pneumocystis pneumonia
Huang, Y., Liu, C.-E., Lin, S., Lee, C., Yang, C., Lin, C., Tang, H.-J., Lee, Y., Lin, Y., Lee, Y., et al. (2019) · AIDS · doi:10.1097/qad.0000000000002207 · Cited by 28
“Copyright © 2019 Wolters Kluwe influence the susceptibility of fungi to echinocandins [25,26].”
BackgroundTripathi, S., Feng, Q. F., Liu, L., Levin, D. E., Roy, K. K., Doerksen, R. J., Baerson, S. R., Shi, X., Pan, X., Xu, W., et al. (2020) · mSphere · doi:10.1128/msphere.00818-19 · Cited by 29
“glabrata strains with FKS mutations have been found to exhibit increased expression of the FKS1 gene (58), which is regulated by the CWI pathway.”
Mechanisms of Antifungal Drug Resistance in Candida Dubliniensis
Coleman, D. C., Moran, G. P., McManus, B. A., & Sullivan, D. J. (2010) · Future Microbiology · doi:10.2217/fmb.10.51 · Cited by 30
Review on fungal enzyme inhibitors – potential drug targets to manage human fungal infections
Ramakrishnan, J., Rathore, S. S., & Raman, T. (2016) · RSC Advances · doi:10.1039/c6ra01577h · Cited by 28
Echinocandins: Addressing outstanding questions surrounding treatment of invasive fungal infections
Holt, S. L., & Drew, R. H. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100456 · Cited by 26
Antifungal resistance does not necessarily affect Candida glabrata fitness
Borghi, E., Andreoni, S., Cirasola, D., Ricucci, V., Sciota, R., & Morace, G. (2014) · Journal of Chemotherapy · doi:10.1179/1973947813y.0000000100 · Cited by 25
Cell Wall-Modifying Antifungal Drugs
Perlin, D. S. (2019) · Current topics in microbiology and immunology · doi:10.1007/82_2019_188 · Cited by 30
Self-citationCandida glabrata, Friend and Foe
Tam, P., Gee, K., Piechocinski, M., & Macreadie, I. G. (2015) · Journal of Fungi · doi:10.3390/jof1020277 · Cited by 29
Fungal echinocandin resistance
Munro, C. A. (2010) · F1000 Biology Reports · doi:10.3410/b2-66 · Cited by 30
“Enzyme kinetics studies have shown that the sensitivity of the mutated glucan synthase to caspofungin is reduced with Ki increasing from 50-fold to several thousand fold depending upon the mutation (Garcia-Effron et al., 2009b; Park et al., 2005).”
BackgroundInfluentialFu, X., Zan, X., Sun, L., Tan, M., Cui, F., Liang, Y., Meng, L., & Sun, W.-J. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c03410 · Cited by 24
Healey, K. R., Paderu, P., Hou, X., Jimenez Ortigosa, C., Bagley, N., Patel, B., Zhao, Y., & Perlin, D. S. (2020) · Journal of Fungi · doi:10.3390/jof6030143 · Cited by 23
“While it has been shown that resistance mutations in FKS genes can alter downstream expression [14], only one mechanism of differential regulation linked to antifungal susceptibility, to our knowledge, has been characterized in C.”
BackgroundSelf-citationLewis, R. E., Liao, G., Hou, J., Prince, R. A., & Kontoyiannis, D. P. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr142 · Cited by 23
Misas, E., Seagle, E. E., Jenkins, E. N., Rajeev, M., Hurst, S. F., Nunnally, N. S., Bentz, M. L., Lyman, M., Berkow, E. L., Harrison, L. H., et al. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.01140-23 · Cited by 26
“Acquired resistance to fluconazole is well-documented (23), and multidrug resistance (MDR), understood here as resistance to at least two classes of antifungal drugs, has been recorded in numerous clinical cases (22, 24, 25).”
Pushing the Limits of MALDI-TOF Mass Spectrometry: Beyond Fungal Species Identification
Rizzato, C., Lombardi, L., Zoppo, M., Lupetti, A., & Tavanti, A. (2015) · Journal of Fungi · doi:10.3390/jof1030367 · Cited by 25
Aigner, M., Erbeznik, T., Gschwentner, M., & Lass‐Flörl, C. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00512-17 · Cited by 26
“Irrespective of the method and CBPs used, isolates harboring these mutations, which result in elevated MICs, should be safely distinguished from wild-type, echinocandin-susceptible isolates (22, 23).”
MethodWhole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Biswas, C., Chen, S. C. ‐., Halliday, C. L., Martinez, E. M., Rockett, R. J., Wang, Q., Timms, V. J., Dhakal, R., Sadsad, R., Kennedy, K., et al. (2017) · Journal of Visualized Experiments · doi:10.3791/56714 · Cited by 23
Saraya, T., Tanabe, K., Araki, K., Yonetani, S., Makino, H., Watanabe, T., Tsujimoto, N., Takata, S., Kurai, D., Ishii, H., et al. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.03593-13 · Cited by 23
The Ins and Outs of Azole Antifungal Drug Resistance: Molecular Mechanisms of Transport
Zavřel, M., Esquivel, B. D., & White, T. C. (2017) · Springer eBooks · doi:10.1007/978-1-4939-0694-9_29 · Cited by 24
“glabrata (Garcia-Effron et al. 2009) and A.”
Evaluation of fungal-specific fluorescent labeled echinocandin probes as diagnostic adjuncts
Pratt, A., García‐Effrón, G., Zhao, Y., Park, S., MUSTAEV, A. A., Pillai, S., & Perlin, D. S. (2012) · Medical Mycology · doi:10.3109/13693786.2012.685767 · Cited by 21
Self-citationAlastruey-Izquierdo, A., Gómez-López, A., Arendrup, M. C., Lass-Florl, C., Hope, W. W., Perlin, D. S., Rodriguez-Tudela, J. L., & Cuenca-Estrella, M. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00791-12 · Cited by 21
“However, several studies found characteristic resistance mechanisms in strains classified as susceptible by these breakpoints (5, 8, 10, 11).”
BackgroundSelf-citationEchinocandin-Resistant Candida: Molecular Methods and Phenotypes
Perlin, D. S. (2011) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0054-x · Cited by 23
Self-citationLim, H. J., Shin, J. H., Kim, M., Yong, D., Byun, S. A., Choi, M. J., Lee, S. Y., Won, E. J., Kee, S., Kim, S. H., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00740-20 · Cited by 20
Self-citationPerrine-Walker, F. M. (2022) · Brazilian Journal of Microbiology · doi:10.1007/s42770-022-00739-9 · Cited by 23
Shor, E., Schuyler, J., & Perlin, D. S. (2019) · mBio · doi:10.1128/mbio.00120-19 · Cited by 19
“In C. glabrata , drug resistance is predominantly caused by point mutations, either in transcription factors regulating drug efflux (13–15) or in genes encoding drug targets (16–18).”
Self-citationEnhanced Efflux Pump Activity in Old Candida glabrata Cells
Bhattacharya, S., & Fries, B. C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02227-17 · Cited by 19
“glabrata strains, a decrease in enzyme function was associated with a relative increase in FKS1 expression (24).”
BackgroundZajac, C., Scott, N. E., Kline, S., Erayil, S. E., & Selmecki, A. M. (2025) · npj Antimicrobials and Resistance · doi:10.1038/s44259-025-00102-6 · Cited by 22
“In C. glabrata , however, both paralogs remain equally expressed in wild-type cells and mutations in either can cause echinocandin resistance 24,26 .”
Clinical utility of antifungal susceptibility testing
McCarty, T. P., Luethy, P. M., Baddley, J. W., & Pappas, P. G. (2022) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlac067 · Cited by 19
Lotfali, E., Fattahi, A., Sayyahfar, S., Ghasemi, R., Rabiei, M. M., Fathi, M., Vakili, K. G., Deravi, N., Soheili, A., Toreyhi, H., et al. (2021) · Microbial Drug Resistance · doi:10.1089/mdr.2020.0235 · Cited by 23
Membrane-Anchored Cyclic Peptides as Effectors of Mitochondrial Oxidative Phosphorylation
Shirey, K., Stover, K. R., Cleary, J. D., Hoang, N., & Hosler, J. P. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01368 · Cited by 19
Self-citation
Metadata
- Authors
- Garcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S.
- Affiliations
- Public Health Research Institute, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, New Jersey 07103
- University of New Mexico (US)
- Rutgers New Jersey Medical School (US)
- University of Mississippi (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-09
- Volume
- 53
- Issue
- 9
- Pages
- 3690-3699
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2737881
- OpenAlex
- W2163061527
- Cited by
- 323
- References
- 40
- Citations by year
- 2026: 18 · 2025: 12 · 2024: 12 · 2023: 14 · 2022: 10 · 2021: 17 · 2020: 22 · 2019: 18 · 2018: 20 · 2017: 26 · 2016: 14 · 2015: 17 · 2014: 25 · 2013: 16 · 2012: 26
- FWCI
- 18.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (AI069397, R01AI069397)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida glabrata, echinocandin resistance, 1,3-β-D-glucan synthase, FKS1, FKS2, hot spot mutations, anidulafungin, micafungin, caspofungin, susceptibility breakpoints, enzyme kinetics, catalytic efficiency, antifungal resistance
- MeSH terms
- Antifungal Agents, Fungal Proteins, Glucosyltransferases, Reverse Transcriptase Polymerase Chain Reaction, Drug Resistance, Fungal, Candida glabrata, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.